Drug Profile

AMX 883

Alternative Names: AMX-883

Latest Information Update: 10 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amphista Therapeutics
Class Antineoplastics
Mechanism of Action BRD9 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Acute myeloid leukaemia

Most Recent Events

08 Dec 2025 Pharmacodynamics data from a preclinical studies in Acute myeloid leukaemia released by Amphista Therapeutics
06 Dec 2025 Adverse events, pharmacokinetic, and pharmacodynamic data from a preclinical trial in Acute myeloid leukaemia presented at the 67^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
06 Dec 2025 Amphista Therapeutics plans a clinical trial for Acute myeloid leukaemia (Second-line therapy or greater) in 2026 (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com